Abstract
There is at present no consensus on the best treatment for AL amyloidosis. Particularly the role of intensive treatment in the management of this disease is not well defiined. So far no comparative trials have been performed. In the series with intensive treatment that have been published1–8 the morbidity and mortality of the procedure are much higher than in multiple myeloma, and the clinical response rate is quite variable (Table 1).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Comenzo RL, Vosburgh E, Simms RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood. 1996; 88:2801–6.
Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91:3662–70.
Comenzo RL, Sanchorawala V, Fisher C et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol. 1999;104:553–9.
Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766–9.
Gillmore JD, Apperley JF, Craddock C. High dose melphalan and stem cell rescue for AL amyloidosis. In Kyle RA, Gertz MA, editors. Amyloid and Amyloidosis. Pearl River, NY: Parthenon, 1998:60.
Gertz MA, Lacy MQ, Gastineau DA et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant. 2000;26:963–9.
Saba N, Sutton D, Ross H et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant. 1999;24:853–5.
Amoura Z, Leblond V, Azar N. High dose therapy and autologous stem cell tarnsplantation (ASCT) for systemic amyloidosis (AL): report on 9 cases. Arthritis Rheum. 1998;41:S234 (abstract).
Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer. 1998;78:774–6.
Persey MR, Lovat LB, Apperley JF, Madhoo S, Pepys MB, Hawkins PN. Intensive chemotherapy for AL amyloidosis. Br J Rheumatol. 1996;35(Suppl.l):12.
Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887–90.
Dhodapkar MV, Jagannath S, Vesole D et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma. 1997;27:351–6.
Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol. 1999; 16:104–9.
Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol. 1999;61:115–19.
Benekli M, Anderson B, Wentling D, Bernstein S, Czuczman M, McCarthy P. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. Bone Marrow Transplant. 2000;25:1299–301.
Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. 1991;77:257–62.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Jaccard, A. (2003). Presentation of the French multicentre randomized trial comparing intensive and conventional treatment for AL amyloidosis. In: Touchard, G., Aucouturier, P., Hermine, O., Ronco, P. (eds) Monoclonal Gammopathies and the Kidney. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-0191-4_21
Download citation
DOI: https://doi.org/10.1007/978-94-017-0191-4_21
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-6199-7
Online ISBN: 978-94-017-0191-4
eBook Packages: Springer Book Archive